The causes of secondary hypertension include diseases and exposures that can recognizably alter the balance between renal excretion, circulating volume, hormonal activity and vascular resistance. They do not constitute a single disease: they are a heterogeneous group in which the same finding, persistently elevated blood pressure, can arise from very different mechanisms and require very different treatments. The value of an etiological assessment lies in identifying a specific therapeutic opportunity and in preventing harm that sometimes extends beyond the mechanical effect of blood pressure.
The kidney plays a central role, both through renal parenchymal diseaseand through the reduction in perfusion that characterizesrenovascular hypertension. Among endocrine disorders,primary aldosteronism is particularly important because of its prevalence and underdiagnosis. Obstructive sleep apnea andexposure to drugs and substances are other clinically important contributors, often superimposed on a primary predisposition.
The frequency of individual causes varies with age and clinical setting. In younger people, kidney diseases, fibromuscular dysplasia, congenital abnormalities and certain inherited conditions assume greater importance; in resistant hypertension, aldosterone, apnea and fluid retention warrant increased attention; in older adults, kidney disease, atherosclerosis and polypharmacy become common. These associations help establish a clinical probabilityrather than rule out a diagnosis because a patient does not fit the most common profile.
The presence of an underlying cause does not always mean that treating it will cure hypertension. Some of the elevation in blood pressure may reflect coexisting factors, and prolonged exposure leaves vascular and renal changes. Successful treatment may therefore manifest as biochemical normalization, fewer medications or reduced risk, even when a degree of hypertension persists. This distinction makes it possible to set realistic expectations without diminishing the importance of investigating the cause.
A useful classification distinguishes renal, endocrine, respiratory, vascular and iatrogeniccauses, while acknowledging overlap. Diseased kidneys can activate hormonal pathways, aldosterone can damage the kidneys, and apnea can amplify sympathetic activity and fluid retention. The categories help organize clinical reasoning but are not independent compartments. In a complex patient, recognizing several contributing factors may be more appropriate than forcing a single explanation.
To establish causation, a finding must be compatible with a mechanism capable of producing the clinical picture. Mild stenosis may be incidental, an adrenal nodule may be nonsecreting, and a minor thyroid abnormality may not explain severe hypertension. Functional activity, severity, chronology and consistency with other findings matter. Improvement after treatment also requires interpretation: it demonstrates a contribution, but may be influenced by simultaneous changes in diet, weight and medication.
The term renal parenchymal disease encompasses glomerular, tubular and interstitial abnormalities, cystic diseases and conditions that reduce the number of functioning nephrons. Blood pressure may rise when the ability to excrete sodium and modulate renal signaling becomes impaired, even before creatinine is markedly elevated. The reverse relationship is equally important: years of high blood pressure can damage the kidneys. Consequently, the coexistence of hypertension and kidney failure does not automatically establish which came first.
The term renal artery stenosis refers to a mechanism involving reduced perfusion and activation of compensatory pathways. Atherosclerosis and fibromuscular dysplasia differ in lesion distribution, affected populations and expected response to intervention. Narrowing can be present without causing hypertension that is correctable by revascularization. A clinical picture involving rapid deterioration or recurrent pulmonary edema raises different questions from stenosis found incidentally in a stable person.
Among adrenal causes,excess aldosterone affects distal sodium transport and the risk of organ damage. It is important not to confuse the term “primary” in this endocrine disorder with primary hypertension: primary aldosteronism is a cause of secondary hypertension. Hypokalemia may be absent, and hypertension need not be resistant. Distinguishing unilateral from bilateral secretion determines whether a targeted surgical or pharmacological strategy is possible.
In functional tumors,hypertension due to pheochromocytoma and paraganglioma results from catecholamine secretion. Blood pressure may be persistently elevated or fluctuate, and some individuals do not exhibit the classic pattern of attacks. The condition also involves hereditary predisposition, possible multiple tumor sites, and the safety of procedures and anesthesia. Its rarity compared with other causes does not lessen the need to recognize it when the clues are convincing.
Inhypertension associated with Cushing syndrome, cortisol contributes to harm through hemodynamic and metabolic effects. Exposure to prescribed glucocorticoids is a separate issue that must be actively investigated. Thyroid diseases instead alter cardiac output, heart rate and vascular tone in ways that depend on the type of dysfunction. A goiter without functional abnormalities does not have the same significance as thyrotoxicosis or clinically relevant hypothyroidism.
The conditionacromegaly can contribute to hypertension through fluid retention, metabolic changes, heart disease and concomitant sleep apnea. Inhyperparathyroidism , the blood pressure association is less directly translatable into a predictable treatment benefit: an epidemiological association alone is not sufficient grounds for parathyroidectomy solely to treat hypertension. Endocrine disorders must therefore be assessed according to the strength of condition-specific evidence, without assigning the same causal significance to every hormonal abnormality.
In aortic coarctation , pressure distribution along the aorta is altered, and persistent hypertension may occur even after repair. The luminal narrowing is part of a broader vascular abnormality, so correcting the gradient does not always normalize all regulatory mechanisms. In drug-induced forms, by contrast, the target may be a modifiable exposure, but any substitution must take into account the disease for which the drug is needed.
The mechanism of sodium retention is common to kidney disease, mineralocorticoid excess and some drug exposures. Initially, extracellular volume may increase; subsequently, the balance between intake and excretion is re-established at a higher blood pressure. Edema or consistently low urinary sodium excretion is therefore not required to recognize sodium's contribution. Clinical assessment must distinguish current balance from the adaptation that makes it possible.
Activation of the renin–angiotensin system may be an appropriate response to reduced renal perfusion but harmful to systemic blood pressure. Conversely, in autonomous aldosterone production, renin tends to be suppressed by volume expansion and increased blood pressure. Two patients with similar readings may therefore have opposite profiles. Medications, age and sodium intake modify these profiles, which must be interpreted as part of a regulated system rather than as isolated labels.
The role of sympathetic stimulation is particularly relevant in sleep-related breathing disorders and adrenergic exposures. Intermittent hypoxia and arousals can produce repeated fluctuations and persistent activation even during the day. In catecholamine-secreting tumors, secretion acts directly on the heart and blood vessels and may be associated with reduced effective circulating volume. Thus, the same elevated blood pressure does not imply the same volume status or the same response to an intervention.
The mechanisms of endothelial dysfunction and increased vascular reactivity link many causes to increased resistance. Cortisol, antiangiogenic drugs and metabolic alterations act through different pathways; in coarctation, an anatomical obstruction and abnormal load distribution are also involved. Over time, remodeling and stiffness become common features and reduce the likelihood of complete reversibility. This progression justifies early diagnosis, before a functional mechanism is accompanied by lasting structural damage.
The existence of monogenic forms shows how specific alterations in channels, transporters or steroid metabolism can produce recognizable blood pressure phenotypes. Potassium levels and acid–base balance can help guide the investigation, but not every presentation is complete. Studying these forms has also clarified mechanisms important to normal physiology; clinically, however, they remain selected diagnoses, to be considered especially with early onset and a family history, without automatically extending genetic testing to every adult with hypertension.
Investigating underlying causes is particularly important inyoung-onset hypertension, sudden loss of blood pressure control and documented resistant hypertension. A history of stable readings followed by an increase after starting a substance may be more informative than a single sophisticated test. A family history does not end the investigation, because it may reflect either a common predisposition or a specific inherited condition. A long period without measurements should also be recognized: a new diagnosis does not necessarily mean a recently developed disease.
History-taking addresses renal symptoms, sleep disturbances, endocrine manifestations and exposures. Physical examination evaluates pulses, inter-arm or inter-limb differences, bruits, signs of congestion and characteristic physical findings. Many secondary forms are nevertheless silent: normal potassium, lack of edema or absence of adrenergic attacks do not exclude primary aldosteronism, a renal contribution or a functional tumor, respectively. Suspicion arises from the overall findings and must be reconsidered if the course does not fit the initial hypothesis.
Before attributing an elevation to disease, the patient's true blood pressure is confirmed by standardized measurement and, when appropriate, home or 24-hour ambulatory monitoring. In Europe, a mean office systolic blood pressure of at least 140 mmHg or diastolic pressure of at least 90 mmHg identifies hypertension but does not reveal its cause. Differences between settings, cuff errors and irregular medication use can mimic a difficult-to-control condition. Correcting these issues prevents the search for a biological explanation of unrepresentative data.
Initial testing evaluates kidney function, electrolytes and urine, metabolic status and baseline cardiac damage. The next step depends on the clinical question: albuminuria and urinary sediment point toward kidney disease; imaging evaluates anatomy and perfusion; aldosterone and renin characterize the mineralocorticoid axis; metanephrines investigate catecholamine secretion; cortisol testing and other assays address endocrine suspicions. Each test has its own preanalytical requirements and limitations, which must be considered before sampling.
An important change concerns screening for primary aldosteronism: the 2025 Endocrine Society guideline suggests it for all people with hypertension, with a conditional recommendation whose implementation depends on resources and expertise. The aldosterone-to-renin ratio is interpreted alongside absolute values and potassium; medications and sodium intake can affect it. This approach broadens detection beyond the hypokalemic phenotype but does not turn every abnormal result into a definitive diagnosis or an indication for surgery.
The anatomical investigation and functional assessment answer different questions. A nodule does not prove secretion, and stenosis does not prove that a procedure would help. For some disorders, it is preferable to establish biological activity first and then localize it; for others, imaging is an early part of evaluation. The appropriate sequence reduces the risk of anchoring on an incidental finding and overlooking a more consistent explanation.
When sleep apneais suspected, questionnaires and history-taking help select those who need sleep recording, whereas diagnosis relies on polysomnography or an appropriate home sleep apnea test. The nocturnal blood pressure pattern may suggest a problem but does not replace respiratory testing. If a limited test is negative and clinical suspicion remains high, a more comprehensive assessment may be needed. Sleep quality during the recording also affects interpretation of 24-hour blood pressure measurements.
Once a cause is identified, its activity and distribution are characterized. In adrenal disease, unilateral and bilateral secretion may need to be distinguished; in vascular disease, hemodynamic significance matters; in kidney disease, the type of lesion, filtration and proteinuria are relevant. Some tumors require genetic assessment and a specific surveillance program. This characterization explains why initial diagnosis and the final choice of treatment may involve different stages.
The degree of hypertension-mediated organ damage is evaluated in parallel. Ventricular hypertrophy, cardiac dysfunction, albuminuria, reduced filtration and retinal signs describe consequences that may be present before symptoms develop. Substantial damage does not, by itself, identify the cause, but changes urgency and expectations. Overall risk also includes age, smoking, lipids, diabetes and previous events; identifying a secondary cause does not make general prevention unnecessary.
The likelihood of reversibility depends on the proportion of disease that remains functional rather than structural. A recent lesion, brief exposure or correctable secretion may offer a greater chance of normalization; a long history accompanied by kidney disease and vascular stiffness may require continued treatment. Not everything can be predicted from the initial blood pressure. Expectations must distinguish correction of the cause, blood pressure control and prevention of events.
Treatment proceeds at two levels: protecting the patient from elevated blood pressure and correcting the responsible mechanism. Investigations must not leave an at-risk patient untreated. When medicines interfere with a test, a safe strategy for interpretation or substitution is chosen, without indiscriminate discontinuation. In emergencies, stabilization and treatment of acute damage take priority; the etiological investigation is incorporated according to the time available and clinical circumstances.
In renal causes, sodium control, treatment of kidney disease and medication adjusted for filtration and albuminuria form the basis of care. Revascularization is not a universal answer to atherosclerotic stenosis: trials have not demonstrated an overall benefit in all patients, and the decision applies to selected situations. Fibromuscular dysplasia is managed according to specific criteria. The technical feasibility of a procedure does not amount to a proven clinical benefit for an individual patient.
In endocrine disorders, targeted therapy may be surgical or medical. In primary aldosteronism, lateralization and suitability for surgery guide adrenalectomy or mineralocorticoid receptor antagonism; in catecholamine-secreting tumors, pharmacological and anesthetic preparation is part of safe care; in hypercortisolism, hormonal excess is reduced while complications are treated concurrently. Endocrine normalization may precede blood pressure normalization and requires monitoring of medications already being taken.
Treatingsleep apnea may improve the blood pressure profile and other clinical outcomes, with the response depending on severity and actual use of therapy. It does not automatically replace antihypertensive medications. For iatrogenic causes, reduction or substitution of the substance is considered together with the physician responsible for its indication; in some cases, it is preferable to continue an essential treatment and control its blood pressure effects. Adherence and interactions become part of the strategy, not separate issues.
After successful correction, medication requirements may decrease, making dose retitrationnecessary. Potassium, renal function and volume status may change rapidly, especially after endocrine procedures or diuretic adjustments. Follow-up verifies both blood pressure control and the persistence of biochemical correction. In diseases with recurrence or familial predisposition, initial remission does not end surveillance.
The prognosis is better when the cause is recognized before advanced damage develops, but a late diagnosis often remains useful. Reducing exposure to high blood pressure, simplifying treatment and addressing specific hormonal effects are clinically meaningful goals even without a complete cure. Success should be judged by the clinical course, organ function and events, not simply by whether the patient takes a tablet.
Common consequences include heart failure, stroke and kidney damage, together with retinopathy and vascular complications. Some causes add their own risks: arrhythmias due to potassium imbalances, catecholamine toxicity, thrombosis and infection in hypercortisolism, or instability associated with aortic lesions. Treatment that lowers only blood pressure may leave these pathways active. Identifying the cause allows the disease to be addressed more comprehensively.
A diagnostic delay prolongs exposure and can make hypertension less reversible. The opposite error is to attribute causation to an incidental finding and undertake procedures without an indication. Between these extremes, an effective approach selects tests and interprets them in context, while remaining open to multiple mechanisms. A negative result does not always exclude disease, and a positive result does not always confirm it: the method, prior probability and biological consistency determine its meaning.
The complications of treatment include hypotension, electrolyte abnormalities, worsening renal function and procedural risks. Prevention requires adequate preparation and a monitoring plan after every major change. Correcting a cause may rapidly alter a physiological state to which the patient and treatment had adapted; the greatest benefit is obtained when targeted treatment is followed by active reassessment rather than simply maintaining the previous regimen.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.